2001
Tolerability Profile of Atypical Antipsychotics in Children and Adolescents
Stigler K, Potenza M, McDougle C. Tolerability Profile of Atypical Antipsychotics in Children and Adolescents. Pediatric Drugs 2001, 3: 927-942. PMID: 11772153, DOI: 10.2165/00128072-200103120-00005.Peer-Reviewed Original ResearchConceptsUse of clozapineExtrapyramidal symptomsAtypical antipsychoticsBodyweight gainTolerability profileGlucose intoleranceBlood glucoseReceptor profileRisk of EPSAdverse effectsCommon adverse effectsLiver function studiesTreatment-refractory diseasePotential treatment optionReceptor interaction profilesOnset of maniaLack of evidenceQTc prolongationBaseline electrocardiogramTreatment optionsSeizure riskCardiovascular illnessClose monitoringClozapineAntipsychotics
1998
Potential of Atypical Antipsychotics in the Treatment of Nonpsychotic Disorders
Potenza M, McDougle C. Potential of Atypical Antipsychotics in the Treatment of Nonpsychotic Disorders. CNS Drugs 1998, 9: 213-232. DOI: 10.2165/00023210-199809030-00005.Peer-Reviewed Original ResearchAtypical antipsychoticsNonpsychotic disordersPharmacological profileDouble-blinded investigationAdverse effect profileUnique pharmacological profileDistinct patient populationsNewer antipsychotic agentsDifferent pharmacological profilesEffect profilePatient populationAntipsychotic agentsAntipsychoticsClinical utilityPsychotic disordersUseful agentPervasive developmental disorderSuch disordersDisordersTolerabilityDrugsFurther studiesTreatmentAggressive behaviorDevelopmental disorders